STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CI Form 144 Notice: Proposed Insider Sale Totals $8.56M

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing for Cigna (CI) reports a proposed sale of 28,526 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,557,800 and approximately 266,928,075 shares outstanding. The shares to be sold were acquired via restricted stock vesting (1,137 shares on 03/01/2024) and option exercises or option-related transactions (2,636 shares on 08/13/2024; 13,155 shares and 11,598 shares with dates shown as 08/15/2025 tied to options granted in 2018 and 2019). No securities were reported sold in the past three months. The filer attests they are not aware of any material nonpublic information.

Positive

  • Complete disclosure of broker, share count, aggregate market value, and acquisition history demonstrating compliance with Rule 144
  • No sales in the past three months are reported, reducing immediate concerns about a pattern of recent insider disposals
  • Attestation that the filer does not possess undisclosed material adverse information

Negative

  • Insider proposed sale of 28,526 shares with an aggregate market value of $8,557,800, representing meaningful insider liquidity

Insights

TL;DR: Insider plans to sell $8.56M of CI stock; filings appear routine and disclose recent option and restricted stock activity.

The notice details a proposed sale of 28,526 common shares with an aggregate market value of $8,557,800 and lists the acquisition sources: restricted stock vesting and option exercises/grants. The filing is procedural under Rule 144 and includes the required attestation about material nonpublic information. There are no reported sales in the prior three months, which suggests this transaction is not part of an ongoing high-frequency disposal pattern disclosed here. For investors, the filing documents insider liquidity but provides no operational or financial performance information.

TL;DR: Filing demonstrates compliance with disclosure rules; the attestation reduces governance-related uncertainty.

The Form 144 supplies the broker, sale timing, share counts, and acquisition history as required, including that the filer represents no undisclosed material adverse information. That representation, together with a clear breakdown of acquisition types (restricted stock vesting and option exercises), reflects adherence to disclosure protocols. The filing does not indicate any unusual arrangements or withheld information, and no prior three-month sales are reported, which is relevant for assessing insider disposal patterns.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for Cigna (CI) report?

The form reports a proposed sale of 28,526 common shares through Fidelity on the NYSE with an aggregate market value of $8,557,800.

When is the approximate date of the proposed sale?

The filing lists the approximate sale date as 08/15/2025.

How were the shares being sold acquired?

Acquisitions listed include restricted stock vesting on 03/01/2024 (1,137 shares), a stock option exercise on 08/13/2024 (2,636 shares), and option-related entries dated 08/15/2025 for 13,155 and 11,598 shares tied to options granted in 2018 and 2019.

Did the filer sell any securities of the issuer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale?

The sale is to be handled by Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI.

Does the filer assert possession of any undisclosed material information?

No. The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Cigna Group

NYSE:CI

CI Rankings

CI Latest News

CI Latest SEC Filings

CI Stock Data

74.35B
262.69M
1.59%
90.15%
1.14%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
BLOOMFIELD